Atypical hemolytic uremic syndrome (aHUS) emerged during the last decade as a disease
largely of complement dysregulation. This advance facilitated the development of novel …

Studies of complement genetics have changed the landscape of thrombotic
microangiopathies (TMAs), particularly atypical haemolytic uraemic syndrome (aHUS) …

Complement activation has a role in the pathogenesis of IgA nephropathy, an autoimmune
disease mediated by pathogenic immune complexes consisting of galactose-deficient IgA1 …

Hematopoietic stem cell transplantation (HSCT)-associated thrombotic microangiopathy (TA-
TMA) is now a well-recognized and potentially severe complication of HSCT that carries a …

The factor H (FH) protein family is emerging as a complex network of proteins controlling the
fate of the complement alternative pathway (AP) and dictating susceptibility to a wide range …

IgA nephropathy (IgAN) is common and often progresses to end stage renal disease. IgAN
encompasses a wide range of histology and clinical features. IgAN pathogenesis is …

Factor H related proteins comprise a group of five plasma proteins: CFHR1, CFHR2,
CFHR3, CFHR4 and CFHR5, and each member of this group binds to the central …

The complement cascade comprises soluble and cell surface proteins and is an important
arm of the innate immune system. Once activated, the complement system rapidly generates …

Thrombotic microangiopathy (TMA) is a condition characterized by thrombocytopenia and
microangiopathic hemolytic anemia (MAHA) with varying degrees of organ damage in the …

IgA nephropathy (IgAN) represents the leading cause of kidney failure among East Asian
populations and the most frequent form of primary glomerulonephritis among Europeans …